Journal of Psychoactive Drugs
August 31, 2023
Alexsandra Kovacevich, Jeremy Weleff, Benjamin Claytor et al.
6 citations
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is limited. A growing body of online media claims that individuals have noticed improvement in anosmia and microsmia following classic psychedelic use. We report what we believe to be the first three cases recorded in the academic literature of...
Molecules
August 31, 2023
Wolfgang Sadee
8 citations
G-protein-coupled receptors (GPCRs) are ubiquitous sensors and regulators of cellular functions. Each GPCR exists in complex aggregates with multiple resting and active conformations. Designed to detect weak stimuli, GPCRs can also activate spontaneously, resulting in basal ligand-free signaling. Agonists trigger a cascade of events leading to an activated agonist-receptor G-protein complex...
Journal of Applied Toxicology
August 30, 2023
Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al.
2 citations
Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...
Highlights in Science, Engineering and Technology
August 29, 2023
Xuehan Du
1 citation
Psilocybin, a psychoactive alkaloid with hallucinogenic properties, exists in a variety of hallucinogenic mushrooms. As a study tool to imitate psychosis, psilocybin has aroused a lot of interest in the biological community due to its various possible therapeutic benefits. It is also a very popular and widely misused natural hallucinogens with distinct metabolism pathways and toxicity. In this...
Expert Opinion on Drug Safety
August 28, 2023
Roger S McIntyre
16 citations
KEYWORDS: Psychedelicpsilocybinlysergic acid diethylamidemood disordersantidepressantsdiscoverypharmacologyFDA
Journal of Psychoactive Drugs
August 24, 2023
Stanley Wong, An Yi Yu, Nicholas Fabiano et al.
11 citations
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...
Scientific Reports
August 22, 2023
Hannes Kettner, Stephen Ross, Richard J. Zeifman et al.
31 citations
Abstract Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging...
Journal of Psychedelic Studies
August 21, 2023
Benjamin M. Ross, James T. Neill
6 citations
Abstract Background Psilocybin, the psychoactive compound in magic mushrooms, is increasingly discussed in terms of its psychotherapeutic potential; however, little is known about community attitudes towards psilocybin assisted therapy (PAT). Aims To address the question: What are the public's attitudes towards psilocybin and psilocybin-assisted therapy? And what factors explain these...
Journal of Psychoactive Drugs
August 21, 2023
Caroline Rutherford, Austin Le, Joseph J Palamar et al.
2 citations
Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival attendees, typically those who attend electronic dance music (EDM) events. We sought to determine whether the use of different drug types varies seasonally within this population. Across 15 seasons from summer 2017 through fall 2022, we surveyed 3,935...
Expert Opinion on Drug Safety
August 15, 2023
Roger S McIntyre
26 citations
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance
Health Sciences Review
August 12, 2023
Burak Okumuş, Ahmet Metin, İ. Afşin Kariper
4 citations
This review is on lysergic acid diethylamide (LSD), which has a halogenic effect and is addictive. Up to now, LSD has been used for pleasure-inducing or spiritual purposes. Since it is soluble in water, it can be administered in different forms. The final decision about whether it is addictive or not is undecided. The use of LSD is extensive and is also used for treating psychiatric disorders...
Journal of Psychopharmacology
August 12, 2023
Michael Tagen, Daniel Mantuani, Alex Holstein et al.
39 citations
Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...
International Journal of Molecular Sciences
August 7, 2023
Alexander Pilozzi, Simmie Foster, David Mischoulon et al.
16 citations
Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...
Australian Journal of Chemistry
July 7, 2023
Michael J. Nutt, Nick Woolf, Scott G. Stewart
2 citations
In this short primer we will discuss the total synthesis of lysergic acid, an important precursor to both lysergic acid diethylamide (LSD) and its derivatives. Lysergic acid is also noted as a precursor for many drugs targeting the serotonin receptor family of GPCRs, including multiple known hallucinogens. More recently, reinvigorated interest in the therapeutic potential of psychedelics from...
Research Square
July 7, 2023
Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al.
4 citations
preprint
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in...
Current Topics in Medicinal Chemistry
July 6, 2023
Udoka C. Ezeaka, Hye Ji J. Kim, Robert B. Laprairie
1 citation
Abstract: Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will summarize the evidence...
Australian Journal of Chemistry
July 4, 2023
Scott R. Walker, Glenn A. Pullella, Matthew Piggott et al.
5 citations
The science of psychedelics is an intriguing, multi-disciplinary field that has recently been the subject of heightened public interest. This has mainly resulted from publicity associated with a number of high-profile investigations into psychedelic-assisted therapy for a range of difficult-to-treat mental health conditions. With many psychedelic substances known, including natural,...
Medicine Conflict & Survival
July 3, 2023
Edgar Jones
2 citations
The current research into psychedelic-assisted psychotherapy for those with severe or complex post-traumatic stress disorder (PTSD) has the potential to be a breakthrough treatment and would begin ...
The Brown University Psychopharmacology Update
July 1, 2023
A randomized trial involving healthy adult men has found that microdosing of lysergic acid diethylamide (LSD) over a 6‐week period resulted in improved effects on mood during dose days. No longer‐term improvements in mood or cognition were reported. Study results were published online March 28, 2023, in Biological Psychiatry.
Forensic Toxicology
July 1, 2023
Rie Tanaka, Maiko Kawamura, Sakumi Mizutani et al.
18 citations
Many analogs of lysergic acid diethylamide (LSD) have recently appeared as designer drugs around the world. These compounds are mainly distributed as sheet products. In this study, we identified three more newly distributed LSD analogs from paper sheet products. The structures of the compounds were determined by gas chromatography-mass spectrometry (GC-MS), liquid chromatography-photodiode...